DGAP-News: Evonik Industries AG / Key word(s): Half Year Results Evonik Industries AG: Evonik specifies outlook for 2016 following a good second quarter 05.08.2016 / 07:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Embargoed until 7 a.m. on August 5, 2016 Key Financial Data: First half/second quarter 2016 Evonik specifies outlook for 2016 following a good second quarter - Evonik increases volumes in the first six months - Adjusted EBITDA margin continues at very good level of 18.1 percent in the first six months - Adjusted net income above EUR500 million - Outlook for the full year specified: adjusted EBITDA in the upper half of the anticipated range of EUR2.0 billion to EUR2.2 billion Essen. Demand for Evonik's products rose worldwide in the first half of this year. "We were able to increase volumes in persistently challenging business conditions," said Klaus Engel, Chairman of the Executive Board of Evonik Industries. "We are now confident that over the full year we will deliver adjusted EBITDA in the upper half of the anticipated range of EUR2.0 to EUR2.2 billion." Evonik registered considerable volume growth in the first six months of 2016, mainly as a result of growth in the second quarter. Despite the higher volumes, Group sales declined to EUR6,363 million, a drop of 8 percent compared with the first half of 2015, principally because lower raw material costs were passed on to customers. Adjusted EBITDA was also below the exceptionally strong prior-period figure at EUR1,150 million. Evonik once again posted a very good adjusted EBITDA margin of 18.1 percent in the first half of 2016. Adjusted EBIT fell 18 percent to EUR795 million in the first six months. Adjusted net income declined 20 percent to EUR501 million. Net income was EUR405 million, down 40 percent from the high prior-year level, which contained the proceeds from the divestment of the stake in Vivawest. Capital expenditures for property, plant and equipment were EUR371 million in the first six months of 2016, down 2 percent year-on-year. Despite the lower operating result, Evonik's free cash flow of EUR208 million was higher than in the first half of 2015 (EUR166 million). This was due, among others, to a considerable reduction in net working capital. Segment performance In the Nutrition & Care segment, lower selling prices accompanied by almost unchanged volumes resulted in a drop in both sales and earnings. In the Resource Efficiency segment higher volumes increased sales and earnings. Higher volumes and lower raw material prices improved earnings in the Performance Materials segment despite a reduction in selling prices. Outlook Evonik still expects to report slightly lower sales in 2016 (2015: EUR13.5 billion). Thanks to its strong market positions, balanced portfolio and concentration on high-growth businesses, the company assumes continued high demand for its products and appreciable volume growth despite the difficult macro-economic conditions. The new production capacities taken into service in recent years and further intensification of sales activities are also contributing to this. Selling prices are declining considerably, especially in the Nutrition & Care and Performance Materials segments, leading to a slight reduction in overall sales. Based on the good business performance, especially in the second quarter, and the expectations for the second half of the year, Evonik is specifying its outlook for the full year: The company is confident that it can realize adjusted EBITDA in the upper half of the anticipated range of EUR2.0 to EUR2.2 billion. Business performance in Q2 2016 In the second quarter of 2016 Group sales dropped 7 percent year-on-year to EUR3,258 million. While volumes increased in all three chemical segments, the decline in sales was principally attributable to the fact that selling prices were lower than in the prior-year period. Adjusted EBITDA was EUR585 million, 11 percent lower than in the exceptionally strong prior-year quarter. The adjusted EBITDA margin was very good at 18.0 percent. Adjusted EBIT fell 16 percent to EUR406 million. Adjusted net income dropped 20 percent to EUR246 million. Overall, net income was EUR165 million. That was below the prior-period level of EUR418 million, which contained the proceeds from the divestment of the stake in Vivawest. Details of segment performance In the second quarter of 2016, the Nutrition & Care segment's sales fell 11 percent to EUR1,111 million. This was mainly attributable to lower selling prices as volume sales increased. Adjusted EBITDA was EUR264 million, which was below the very high prior-year level of EUR381 million, mainly on price grounds. The adjusted EBITDA margin dropped to 23.8 percent. In the first six months of 2016 this segment's sales dropped by 13 percent to EUR2,157 million. While volumes were almost unchanged, lower selling prices were the main reason for the decline. Adjusted EBITDA was 24 percent below the very strong prior-year level at EUR557 million. The adjusted EBITDA margin is still excellent at 25.8 percent. Business continued to develop pleasingly in the Resource Efficiency segment in the second quarter: Sales rose 4 percent to EUR1,156 million. The main drivers were higher global demand and the activities acquired in 2015. This was countered by a slight reduction in selling prices. Adjusted EBITDA improved 6 percent to EUR270 million, mainly as a consequence of higher volumes, favorable raw material costs and positive currency effects. The adjusted EBITDA margin improved to a very good 23.4 percent. In the first six months of the year, this segment's sales rose 2 percent to EUR2,276 million, driven principally by higher volumes. Lower selling prices had a counter-effect. Adjusted EBITDA increased 6 percent to EUR526 million. The adjusted EBITDA margin improved to 23.1 percent (H1 2015: 22.3 percent). In the Performance Materials segment, sales dropped 12 percent to EUR829 million in the second quarter, principally owing to lower selling prices as a result of the reduction in raw material prices. By contrast, volumes rose considerably thanks to good demand. Adjusted EBITDA rose by 28 percent to EUR105 million. This was principally due to a rise in volumes, improved raw material efficiency and systematic cost management. The adjusted EBITDA margin was 12.7 percent, up from 8.7 percent in the second quarter of 2015. Sales in the Performance Materials segment fell 10 percent to EUR1,601 million in the first six months of 2016. With volumes up, the decline was caused by the oil-driven drop in selling prices. Adjusted EBITDA improved 10 percent to EUR169 million. The adjusted EBITDA margin improved to 10.6 percent. Evonik Group: Excerpt from the income statement (in EUR million) Q2 2016 Q2 Change H1 H1 Change 2015 in % 2016 2015 in % Sales 3,258 3,519 -7 6,363 6,944 -8 Adjusted EBITDA 585 661 -11 1,150 1,311 -12 Adjusted EBIT 406 486 -16 795 971 -18 Adjustments -47 122 -59 85 Financial result -93 -51 -128 -114 Income before 266 557 -52 608 942 -35 income taxes, continuing operations Income taxes -97 -133 -195 -249 Income after taxes, 169 424 -60 413 693 -40 continuing operations Income after taxes, -1 -5 -1 -15 discontinued operations Income after taxes 168 419 -60 412 678 -39 thereof 3 1 7 4 attributable to non-controlling interests Net income 165 418 -61 405 674 -40 Adjusted net income 246 307 -20 501 627 -20 Prior-year figures restated Segment performance Sales Q2 Adjusted EBITDA Q2 2016 2015 Change 2016 2015 Change EUR EUR in % EUR EUR in % million million million million Nutrition & 1,111 1,248 -11 264 381 -31 Care Resource 1,156 1,110 4 270 254 6 Efficiency Performance 829 938 -12 105 82 28 Materials Services 163 211 -23 33 28 18 Other -1 12 - -87 -84 -4 operations / consolidation Group 3,258 3,519 -7 585 661 -11 Sales H1 Adjusted EBITDA H1 2016 2015 Change 2016 2015 Change EUR EUR in % EUR EUR in % million million million million Nutrition & 2,157 2,476 -13 557 734 -24 Care Resource 2,276 2,233 2 526 498 6 Efficiency Performance 1,601 1,788 -10 169 154 10 Materials Services 330 419 -21 68 74 -8 Other -1 28 - -170 -149 -14 operations / consolidation Group 6,363 6,944 -8 1,150 1,311 -12 Employees by segment June 30, 2016 Dec. 31, 2015 Nutrition & Care 7,369 7,165 Resource Efficiency 8,758 8,662 Performance Materials 4,376 4,380 Services 12,737 12,668 Other operations 502 701 Group 33,742 33,576 Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion. Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations Phone +49 201 177-3150 [email protected] Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Christian Kullmann, Deputy Chairman Dr. Ralph Sven Kaufmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 --------------------------------------------------------------------------- 05.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: [email protected] Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 489539 05.08.2016